# EDGAR Filing Document

**Accession Number:** 0001573160
**File Stem:** 0000899243-23-005992
**Filing Date:** 2023-2
**Character Count:** 7886
**Document Hash:** 097794f6f99166fee1ceeea1b6e26ed5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-005992.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0000899243-23-005992

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230222

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Huang James
- **CENTRAL INDEX KEY:** 0001573160

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39290
- **FILM NUMBER:** 23660136

**MAIL ADDRESS:**
- **STREET 1:** 9620 MEDICAL CENTER DRIVE
- **STREET 2:** SUITE 300
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WINDTREE THERAPEUTICS INC /DE/
- **CENTRAL INDEX KEY:** 0000946486
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 943171943
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2600 KELLY ROAD
- **STREET 2:** SUITE 100
- **CITY:** WARRINGTON
- **STATE:** PA
- **ZIP:** 18976
- **BUSINESS PHONE:** 2154889300

**MAIL ADDRESS:**
- **STREET 1:** 2600 KELLY ROAD
- **STREET 2:** SUITE 100
- **CITY:** WARRINGTON
- **STATE:** PA
- **ZIP:** 18976

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DISCOVERY LABORATORIES INC /DE/
- **DATE OF NAME CHANGE:** 19971201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANSAN PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19961121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANSAN INC
- **DATE OF NAME CHANGE:** 19950609

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Huang James<br><sub>(Last) (First) (Middle)</sub><br>C/O WINDTREE THERAPEUTICS, INC.<br>2600 KELLY ROAD, SUITE 100<br><sub>(Street)</sub><br>WARRINGTON, PA 18976<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-22 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>WINDTREE THERAPEUTICS INC /DE/ [ WINT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-22 |  | X |  | 1112308 | A | $0.1411 | 3449161 | I | See Footnote<sup>(1)</sup> |
| Common Stock |  |  |  |  |  |  |  | 296281 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrants (right to purchase) | $7.975 | 2023-02-22 |  | D<sup>(2)</sup> |  |  | 275862 | 2020-05-22 | 2025-05-22 | Common Stock | 275862 | $0.00 | 0 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $12.09 | 2023-02-22 |  | D<sup>(2)</sup> |  |  | 275938 | 2020-06-06 | 2024-12-06 | Common Stock | 275938 | $0.00 | 0 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $12.15 | 2023-02-22 |  | D<sup>(2)</sup> |  |  | 498008 | 2018-12-24 | 2023-12-24 | Common Stock | 498008 | $0.00 | 0 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $12.00 | 2023-02-22 |  | D<sup>(2)</sup> |  |  | 62500 | 2019-01-02 | 2023-07-02 | Common Stock | 62500 | $0.00 | 0 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $0.1411 | 2023-02-22 |  | A<sup>(2)</sup> |  | 1112308 |  | 2023-02-22 | 2023-02-22 | Common Stock | 1112308 | $0.00 | 1112308 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $0.1411 | 2023-02-22 |  | X |  |  | 1112308 | 2023-02-22 | 2023-02-22 | Common Stock | 1112308 | $0.00 | 0 | I | See Footnote<sup>(1)</sup> |
| Warrants (right to purchase) | $0.2152 | 2023-02-22 |  | A<sup>(2)</sup> |  | 2224616 |  | 2023-08-21 | 2028-08-21 | Common Stock | 2224616 | $0.00 | 2224616 | I | See Footnote<sup>(1)</sup> |

---

### Footnotes:

(1) Represents securities held by Panacea Venture Healthcare Fund I L.P. ("Panacea Healthcare"), over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.

(2) Pursuant to a warrant exercise inducement offer letter, the Issuer and Panacea Healthcare agreed to amend the outstanding warrants held by Panacea Healthcare to lower the exercise price to $0.1411 and to issue Panacea Healthcare warrants to purchase an additional 2,224,616 shares of Common Stock, in exchange for Panacea Healthcare agreeing to immediately exercise the repriced warrants.

**Signature:** /s/ James Huang  
**Date:** 2023-02-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**